Home
HelpTest Code ASPBA Aspergillus Antigen, Bronchoalveolar Lavage
Reporting Name
Aspergillus Ag, BALUseful For
Aiding in the diagnosis of invasive aspergillosis using bronchoalveolar lavage specimens
Assessing response to therapy
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
LavageOrdering Guidance
For serum specimens, order ASPAG / Aspergillus (Galactomannan) Antigen, Serum.
Specimen Required
Container/Tube: Sterile, leak-proof container
Note: Specimen trap collection containers (with suction catheters attached) will be rejected due to high-risk of leakage and contamination upon opening. Avoid use of these for bronchoalveolar lavage specimens.
Specimen Volume: 2 mL
Additional Information: If specimen transfer into an acceptable sterile container is necessary, perform specimen transfer in a biosafety cabinet. Place container in separate sealed plastic bag.
Specimen Minimum Volume
1.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Lavage | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days |
Reference Values
<0.5 Index
Day(s) Performed
Monday through Friday, Sunday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
87305
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ASPBA | Aspergillus Ag, BAL | 62467-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 61009 | Aspergillus Ag, BAL | 62467-6 |
Interpretation
A positive result in bronchoalveolar lavage (BAL) fluid supports a diagnosis of invasive, pulmonary aspergillosis. Positive results should be considered in conjunction with other diagnostic procedures, such as microbiologic culture, histological examination of biopsy specimens, and radiographic evidence (see Cautions).
A negative result in BAL fluid does not rule out the diagnosis of invasive aspergillosis (IA). Patients at risk of IA should be monitored twice a week for Aspergillus antigen levels in serum until determined to be clinically unnecessary.
Aspergillus antigen levels typically decline in response to effective antimicrobial therapy.
Clinical Reference
1. Park SY, Lee SO, Choi SH, et al: Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect. 2010 Dec;61(6):492-498
2. Husain S, Clancy CJ, Nguyen MH, et al: Performance characteristics of the platelia aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol. 2008 Dec;15(12):1760-1763
3. Meersseman W, Lagrou K, Maertens J, et al: Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008 Jan 1;177(1):27-34
4. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S: Galactomannan detection in computerized tomography-based bronchoalveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol. 2003 May;121(3):448-457
5. Xavier MO, Pasqualotto AC, Cardoso ICE, Severo LC: Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2009 Jan;16(1):132-133
6. Thompson GR, Patterson TF: Aspergillus species. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:3103-3116
Report Available
1 to 2 daysMethod Name
Enzyme Immunoassay (EIA)
Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.